Immucell Corp ICCC
We take great care to ensure that the data presented and summarized in this overview for IMMUCELL CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ICCC
View all-
Cresset Asset Management, LLC Chicago, IL264KShares$1.25 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA226KShares$1.06 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny149KShares$705,5880.0% of portfolio
-
Bleichroeder LP New York, NY102KShares$479,5230.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX72.7KShares$343,0590.0% of portfolio
-
Morgan Stanley New York, NY63.5KShares$299,7950.0% of portfolio
-
Shufro Rose & CO LLC62.4KShares$294,5650.02% of portfolio
-
Geode Capital Management, LLC Boston, MA56.7KShares$267,4350.0% of portfolio
-
Strategic Financial Services, Inc, Utica, NY31KShares$146,3200.01% of portfolio
-
Northern Trust Corp Chicago, IL29.4KShares$138,7300.0% of portfolio
Latest Institutional Activity in ICCC
Top Purchases
Top Sells
About ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Insider Transactions at ICCC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 28
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
2,186
+1.63%
|
$6,558
$3.55 P/Share
|
Aug 23
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
6,005
+4.43%
|
$18,015
$3.55 P/Share
|
Aug 22
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
10,000
+7.48%
|
$30,000
$3.55 P/Share
|
Aug 19
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
3,172
+2.72%
|
$9,516
$3.67 P/Share
|
Aug 16
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
4,811
+4.17%
|
$14,433
$3.72 P/Share
|
Aug 15
2024
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
2,017
+1.87%
|
$6,051
$3.57 P/Share
|
Sep 06
2023
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
3,100
+2.91%
|
$12,400
$4.75 P/Share
|
Mar 14
2023
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,880
+0.13%
|
$9,400
$5.52 P/Share
|
Mar 14
2023
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
100
+0.1%
|
$500
$5.53 P/Share
|
Mar 13
2023
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
2,100
+0.21%
|
$10,500
$5.26 P/Share
|
Sep 12
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
801
+0.41%
|
$5,607
$7.78 P/Share
|
Sep 09
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
700
+0.24%
|
$4,900
$7.75 P/Share
|
Sep 08
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
906
+0.16%
|
$6,342
$7.69 P/Share
|
Jun 14
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
650
+0.23%
|
$5,200
$8.13 P/Share
|
Jun 13
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,485
+0.27%
|
$10,395
$7.79 P/Share
|
Jun 13
2022
|
David Cunningham Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.88%
|
$8,000
$8.0 P/Share
|
Jun 09
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,500
+0.33%
|
$12,000
$8.51 P/Share
|
Jun 07
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
53
+0.06%
|
$424
$8.18 P/Share
|
Jun 02
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
112
+0.12%
|
$896
$8.2 P/Share
|
Jun 01
2022
|
David Scott Tomsche |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,100
+0.41%
|
$8,800
$8.25 P/Share
|
Last 12 Months Summary
Sale (or disposition) back to the issuer | 28.2K shares |
---|